Dose-dense adjuvant chemotherapy in HER2-positive early breast cancer patients before and after the introduction of trastuzumab: Exploratory analysis of the GIM2 trial.
Lambertini M, Poggio F, Bruzzone M, Conte B, Bighin C, de Azambuja E, Giuliano M, De Laurentiis M, Cognetti F, Fabi A, Bisagni G, Durando A, Turletti A, Urracci Y, Garrone O, Puglisi F, Montemurro F, Ceppi M, Del Mastro L; GIM2 investigators.
Lambertini M, et al. Among authors: de azambuja e, de laurentiis m.
Int J Cancer. 2020 Jul 1;147(1):160-169. doi: 10.1002/ijc.32789. Epub 2019 Dec 4.
Int J Cancer. 2020.
PMID: 31724170